- Home
- BGNE vs BAX Comparison
BGNE vs BAX Comparison
Compare BGNE & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- BAX
- Stock Information
- Founded
- BGNE 2010
- BAX 1931
- Country
- BGNE Cayman Islands
- BAX United States
- Employees
- BGNE N/A
- BAX N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- BAX Medical/Dental Instruments
- Sector
- BGNE Health Care
- BAX Health Care
- Exchange
- BGNE Nasdaq
- BAX Nasdaq
- Market Cap
- BGNE 21.0B
- BAX 17.3B
- IPO Year
- BGNE 2016
- BAX N/A
- Fundamental
- Price
- BGNE $189.23
- BAX $31.92
- Analyst Decision
- BGNE Buy
- BAX Hold
- Analyst Count
- BGNE 7
- BAX 10
- Target Price
- BGNE $247.07
- BAX $41.40
- AVG Volume (30 Days)
- BGNE 281.8K
- BAX 3.6M
- Earning Date
- BGNE 11-12-2024
- BAX 11-08-2024
- Dividend Yield
- BGNE N/A
- BAX 3.63%
- EPS Growth
- BGNE N/A
- BAX N/A
- EPS
- BGNE N/A
- BAX 0.21
- Revenue
- BGNE $3,351,304,621.00
- BAX $15,062,000,000.00
- Revenue This Year
- BGNE $969.39
- BAX $3.81
- Revenue Next Year
- BGNE $24.79
- BAX $3.45
- P/E Ratio
- BGNE N/A
- BAX $134.25
- Revenue Growth
- BGNE 50.22
- BAX 32.37
- 52 Week Low
- BGNE $126.97
- BAX $31.60
- 52 Week High
- BGNE $248.16
- BAX $44.01
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- BAX 19.35
- Support Level
- BGNE $189.60
- BAX $31.61
- Resistance Level
- BGNE $209.29
- BAX $36.82
- Average True Range (ATR)
- BGNE 6.42
- BAX 0.82
- MACD
- BGNE -2.10
- BAX -0.41
- Stochastic Oscillator
- BGNE 9.19
- BAX 3.17
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About BAX Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.